Xanodyne Acquires aaiPharma Assets
Xanodyne Acquires aaiPharma Assets
Xanodyne Pharmaceuticals (Florence, KY) was named the winning bidder last Tuesday, July 12, in an auction that decided the fate of aaiPharma’s pharmaceuticals division. Xanodyne acquired all company assets in bankruptcy court for $209.25 million. The company also said that it will purchase $30 million in services to be supplied by the development services division of aaiPharma.
As part of the acquisition, Xanodyne will gain pain management drugs, “Darvon” and “Darvocet,” as well as three pain products in clinical development. The additional products are expected to bring in pro-forma 2005 revenues of nearly $100 million.
“We have believed for some time that the two businesses fit very well together,” said William Nuerge, CEO of Xanodyne. “Xanodyne brings a pipeline of women’s healthcare products and a strong commercial capability and infrastructure for both women’s healthcare and pain management products, while aaiPharma has a broad range of currently marketed and pipeline pain products.”
In other news, Xanodyne’s board of directors was reshuffled to guide the company through the purchase and merger. Members James Cavanaugh, James Currie, and Nuerge remain on the board and will be joined by Ansbert Gadicke, Steven St. Peter, Adele Oliva and Dennis Purcell. Cavanaugh continues as chairman of the board.
-George Koroneos
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
